Cefepime Dosing for Creatinine Clearance 50 mL/min
For an adult patient with a creatinine clearance of 50 mL/min, adjust cefepime to 2 g every 24 hours for most indications, or 2 g every 12 hours specifically for febrile neutropenia or severe Pseudomonas infections.
Standard Dosing Adjustments
According to the FDA-approved dosing schedule, patients with CrCl of 30-60 mL/min require the following adjustments 1:
- Standard infections (pneumonia, UTI, skin/soft tissue): 2 g every 24 hours
- Febrile neutropenia or severe infections requiring q8h dosing: 2 g every 12 hours
- Mild-moderate infections requiring 1 g q12h: 1 g every 24 hours
- Mild infections requiring 500 mg q12h: 500 mg every 24 hours
The initial loading dose should remain the same as for patients with normal renal function—only the maintenance dosing interval changes 1.
Key Clinical Considerations
Pharmacokinetic Profile at CrCl 50 mL/min
At this level of renal function, cefepime elimination is moderately impaired. Research demonstrates that patients with CrCl 60-100 mL/min have significantly higher trough concentrations (19.5 ± 21.5 mg/L) compared to those with CrCl >100 mL/min (3.3 ± 3.6 mg/L) 2. Your patient at CrCl 50 mL/min falls into the range requiring dose adjustment to prevent accumulation.
Risk of Neurotoxicity
This is critical: Even with appropriate dose adjustment, patients with CrCl 30-60 mL/min remain at risk for cefepime-induced neurotoxicity (CIN). Studies show that 10% of patients with renal impairment developed symptoms compatible with non-convulsive epilepsy (confusion, muscle jerks) despite dosage adjustment 3. The risk increases substantially when trough concentrations exceed 20 mg/L 4.
Monitoring Requirements
For patients with CrCl around 50 mL/min:
- Monitor renal function daily during the first week, then every 2-3 days
- Assess neurological status daily: confusion, altered mental status, myoclonus, or seizures
- Consider therapeutic drug monitoring (TDM) if available, targeting trough concentrations <20 mg/L to minimize neurotoxicity risk while maintaining efficacy 3, 4
- Administer doses at the same time each day for consistency 1
Pharmacodynamic Target Attainment
The adjusted dosing of 2 g every 24 hours achieves adequate pharmacodynamic targets (T>MIC ≥50-70%) for pathogens with MIC ≤4 mg/L 2. However, for less susceptible organisms (MIC 8 mg/L, such as some Pseudomonas aeruginosa), standard dosing may be suboptimal even after adjustment 2, 5.
If treating Pseudomonas or other organisms with MIC ≥8 mg/L: Consider using 2 g every 12 hours (rather than every 24 hours) with close monitoring, or consider alternative agents if neurotoxicity concerns arise.
Special Situations
Fluctuating Renal Function
If renal function is unstable or worsening, reassess dosing every 24-48 hours. The half-life of cefepime increases proportionally with declining renal function (from 2.3 hours in normal function to 13.5 hours in severe impairment) 6.
Critical Illness
Critically ill patients demonstrate substantial interpatient pharmacokinetic variability 7. If your patient is septic or in the ICU, TDM becomes even more important as standard dosing adjustments may not reliably predict drug exposure 3, 8.